Efficacy of Adding Once-Daily Insulin Glulisine in Japanese Type 2 Diabetes Patients Treated with Insulin Glargine and Sitagliptin

2014 ◽  
Vol 16 (10) ◽  
pp. 633-639 ◽  
Author(s):  
Mitsuyoshi Takahara ◽  
Toshihiko Shiraiwa ◽  
Naoto Katakami ◽  
Taka-aki Matsuoka ◽  
Iichiro Shimomura
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Once Daily ◽  
Daily Insulin ◽  
Insulin Glulisine ◽  
Diabetes Patients

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-naïve subjects with type 2 diabetes (SUSTAIN 4)

2016 ◽  
Vol 120 ◽  
pp. S51 ◽  
Author(s):  
Vanita Aroda ◽  
Stephen Bain ◽  
Bertrand Cariou ◽  
Milivoj Piletic ◽  
Ludger Rose ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Efficacy And Safety ◽  
Once Daily ◽  
Daily Insulin

scholarly journals Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

2021 ◽  
Author(s):  
Harpreet S. Bajaj ◽  
Richard M. Bergenstal ◽  
Andreas Christoffersen ◽  
Melanie J. Davies ◽  
Amoolya Gowda ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Oral Glucose ◽  
Loading Dose ◽  
Phase 2 ◽  
Once Daily ◽  
Daily Insulin ◽  
Significant Difference

<b>OBJECTIVE</b><br><b></b><p><b> </b>Insulin icodec (icodec) is a novel once-weekly basal insulin analog. This trial investigated two approaches for switching to icodec versus once-daily insulin glargine U100 (IGlar U100) in people with type 2 diabetes receiving daily basal insulin and ≥1 oral glucose-lowering medication.</p> <p><b>RESEARCH DESIGN AND METHODS</b><br> This multicenter, open-label, treat-to-target phase 2 trial randomized (1:1:1) eligible basal-insulin-treated (total daily dose 10–50 U) people with type 2 diabetes (HbA<sub>1c</sub> 7.0–10.0% [53.0–13.3 mmol/mo]) to icodec with an initial 100% loading dose (where only the first dose was doubled; icodec LD), icodec with no loading dose (icodec NLD) or IGlar U100 for 16 weeks. Primary endpoint was percent time in <a>range (TIR; 3.9–10.0 mmol/L [70–180 mg/dL]) </a>during weeks 15 and 16, measured using continuous glucose monitoring. Key secondary endpoints included HbA<sub>1c</sub>,<sub> </sub>adverse events (AEs) and hypoglycemia. </p> <p><b>RESULTS</b><br> Estimated mean TIR during weeks 15 and 16 was 72.9% (icodec LD; <i>n</i> = 54), 66.0% (icodec NLD; <i>n</i> = 50) and 65.0% (IGlar U100; <i>n</i> = 50), with a statistically significant difference favoring icodec LD versus IGlar U100 (7.9%-points, 95% CI 1.8 to 13.9%). Mean HbA<sub>1c</sub> reduced from 7.9% (62.8 mmol/mol) at baseline to 7.1% ([54.4 mmol/mol] icodec LD) and 7.4% ([57.6 mmol/mol] icodec NLD and IGlar U100); incidences and rates of AEs and hypoglycemic episodes were comparable.<br> <br> </p> <p><b>CONCLUSIONS</b><br> Switching from daily basal insulin to once-weekly icodec was well tolerated and provided effective glycemic control. Loading dose use when switching to once-weekly icodec significantly increased percent TIR during weeks 15 and 16 versus once-daily IGlar U100, without increasing hypoglycemia risk.</p>

Abstract #290: Efficacy and Safety of Once-Weekly Semaglutide Vs Once-Daily Insulin Glargine in Insulin-NAÏVE Subjects with Type 2 Diabetes (Sustain 4)

2016 ◽  
Vol 22 ◽  
pp. 79
Author(s):  
Vanita Aroda ◽  
Stephen Bain ◽  
Bertrand Cariou ◽  
Milivoj Piletic ◽  
Ludger Rose ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Efficacy And Safety ◽  
Once Daily ◽  
Daily Insulin
Sign in / Sign up

Export Citation Format

Share Document